MOB.ST - Moberg Pharma AB (publ)

Stockholm - Stockholm Real Time Price. Currency in SEK
+0.85 (+2.59%)
As of 10:03AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close33.15
Bid32.70 x 0
Ask33.70 x 0
Day's Range32.50 - 33.70
52 Week Range22.50 - 51.50
Avg. Volume47,135
Market Cap643.36M
PE Ratio (TTM)36.31
EPS (TTM)0.93
Earnings DateAug 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.80
  • PR Newswirelast month

    Bulletin from Moberg Pharma's AGM 2018

    Moberg Pharma AB's ("Company") Annual General Meeting took place on Tuesday, May 15th, 2018 in the Company´s premises in Bromma. The Annual General Meeting (the "Meeting") approved the income statements and the balance sheets for the fiscal year 2017. In accordance with the proposal of the Nomination Committee, the Meeting resolved that the Board of Directors shall consist of five persons and no deputies.

  • PR Newswirelast month

    Moberg Pharma AB Interim Report January - March 2018

    STOCKHOLM , May 8, 2018 /PRNewswire/ -- SIGNIFICANT GROWTH FOR ALL KEY BRANDS FIRST QUARTER (JAN- MAR 2018 ) Net revenue SEK 91.5 million (104.6) EBITDA SEK 21.9 million (16.7) EBITDA margin 24% (16) EBITDA ...

  • PR Newswire2 months ago

    U.S. Patent Granted for BUPI

    STOCKHOLM , May 2, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently ...

  • PR Newswire2 months ago

    Moberg Pharma Completes Divestment of Balmex® for $4.25 million

    STOCKHOLM , April 27, 2018 /PRNewswire/ --  Moberg Pharma AB (OMX: MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration of $4.25 million plus the inventory value. ...

  • PR Newswire2 months ago

    Management Change in Moberg Pharma

    STOCKHOLM , April 19th, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt , VP Research and Development, will retire in the fall but remain with the company part-time as Senior ...

  • Want To Invest In Moberg Pharma AB (publ) (STO:MOB)? Here’s How It Performed Lately
    Simply Wall St.2 months ago

    Want To Invest In Moberg Pharma AB (publ) (STO:MOB)? Here’s How It Performed Lately

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Moberg Pharma AB (publ)’s (OM:MOB) track record on a high level,Read More...

  • PR Newswire2 months ago

    Moberg Pharma Annual Report 2017

    STOCKHOLM , April 10, 2018 /PRNewswire/ -- Moberg Pharma´s Annual Report for 2017 has been published and is available on About this information Moberg Pharma AB is obliged to make ...

  • PR Newswire3 months ago

    The Nomination Committee's Proposal to the Annual General Meeting 2018

    STOCKHOLM, March 13, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX:MOB) announces that the company's Nomination Committee has decided to present the following proposal to the Annual General Meeting 2018. The Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Fredrik Persson representing Zimbrine Holding BV, Anders Rodebjer representing Wolco Invest and Thomas Eklund, Chairman of the Board of Directors in the Company. The Nomination Committee proposes that Thomas Eklund is elected as Chairman of the Annual General Meeting of shareholders 2018.

  • PR Newswire4 months ago

    Moberg Pharma Divests Balmex® for $4.25 Million

    STOCKHOLM , Feb. 28, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million ( 34.6 million ...

  • PR Newswire4 months ago

    Moberg Pharma AB Year-end Report 2017

    STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA STOCKHOLM , Feb. 13, 2018 /PRNewswire/ -- PERIOD (FULL YEAR 2017)* Net revenue SEK 439.0 million (334.3) EBITDA SEK 89.4 million (77.9) EBITDA margin 20% ...

  • PR Newswire5 months ago

    Moberg Pharma Receives Favorable Outcome From NAD - Main Competitor to Discontinue Current Marketing

    STOCKHOLM , Jan. 15, 2018 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) have received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest ...

  • PR Newswire7 months ago

    Moberg Pharma Reorganizes its Commercial Operations

    STOCKHOLM , Nov. 30th, 2017 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) is reorganizing its sales and marketing operations to better reflect the company's increased focus on the North American market and ...